Publication | Closed Access

Yttrium-90–ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma

Lymphoid NeoplasiaTransplantationMedicinePathologyChemo-refractory Aggressive Non-hodgkinYttrium-90–ibritumomab TiuxetanCancer TreatmentRadiation OncologyOncologyCell TransplantationHigh-dose Beam Chemotherapy